Introduction {#S0001}
============

Anaplastic lymphoma kinase (*ALK*) gene-rearrangement is seen in 2--7% of non-small cell lung cancer (NSCLC).[@CIT0001] Constitutive kinase activity leads to activation of cellular pathways involved in cell growth and proliferation that drive tumorigenesis. This characterizes a molecular subgroup of NSCLC, with other oncogenic drivers considered mutually exclusive. Tyrosine kinase inhibitors (TKIs) are now first-line therapy for such tumors. Although a substantial portion of patients benefit from TKIs, this approach is complicated by intrinsic and acquired resistance.[@CIT0002],[@CIT0003] We report a patient with *ALK*-rearranged NSCLC who showed an initial response to targeted therapy, but developed resistance to multiple TKIs. Serial comprehensive genomic profiling (CGP) revealed a secondary CTNNB1 p.S45V mutation after the initiation of targeted therapy, followed by tertiary ALK p.I1171N, suggesting possible mechanisms for resistance. Written informed consent was provided by the patient to have the case details published. Institutional approval was not required to publish the case details.

Case presentation {#S0002}
=================

A 59-year-old female with passive smoke exposure presented in October 2015 with progressive cough. She had a family history of lung cancer (mother diagnosed at the age of 78 years; and paternal grandfather); urinary bladder cancer (mother diagnosed at the age of 74 years; maternal uncle at the age of 82 years; and maternal grandfather at the age of 80 years); colon cancer (father diagnosed at the age of 62 years); salivary gland cancer (maternal uncle); and pituitary adenoma (sister at the age of 45 years). A computed tomography scan revealed a 3.7 cm left lower lobe lung lesion. Biopsy and fine needle aspirate of the lung mass demonstrated moderately differentiated adenocarcinoma ([Figure 1](#F0001){ref-type="fig"}). Initially, no somatic mutations were identified by a 26-gene mass spectrometry-based mutation panel on the Agena MassARRAY (Agena Bioscience; San Diego, CA, USA). Fluorescence in situ Hybridization (FISH) was negative for *ROS1*-rearrangement (*ROS1* testing performed at Quest Diagnostics; Chantilly, VA, USA) and did not meet validated criteria for *ALK*-rearrangement. Consequently, the patient was initiated on carboplatin, paclitaxel, and bevacizumab for Stage IV (pT2aN3M1a) disease.Figure 1Representative histologic image from a needle biopsy of a 3.7 cm left lower lobe lung lesion (October 2015). H&E stained slides show well- to moderately differentiated adenocarcinoma with predominantly acinar growth pattern and associated psammomatous calcifications. (20x, H&E).

Subsequent CGP by FoundationOne (Foundation Medicine, Inc.; Cambridge, MA, USA) demonstrated *EML4-ALK* fusion and *RICTOR* amplification. To resolve the discrepancy between CGP and FISH, ALK immunohistochemistry (Novocastra 5A4; Leica Biosystems; Buffalo Grove, IL, USA) was performed to assess for protein expression; testing was positive, revealing increased ALK protein expression ([Figure 2](#F0002){ref-type="fig"}). The patient remained stable on four cycles of chemotherapy, then transitioned to targeted therapy with crizotinib 250 mg twice per day (BID) in January 2016.Figure 2(**A**) ALK immunohistochemical staining of the needle biopsy specimen from October 2015, showing nearly diffuse expression of weak to moderate intensity. No background staining is present (10x, ALK, Novocastra 5A4). For comparison, a negative control is shown (**B**, 10x), consisting of the immunohistochemistry reaction without the primary ALK antibody; the lack of staining in the negative control (**B**) confirms that ALK staining in the patient sample (**A**) is due to the detection of the antigen. A positive control is also shown (**C**, 10x), showing diffuse ALK expression in a sample of an inflammatory myofibroblastic tumor, which is known to express the ALK protein.

After an initial clinical response to crizotinib therapy, the disease clinically progressed with brain metastases in June 2016. Repeat CGP on pleural fluid from June 2016 (while on crizotinib) again showed *EML4-ALK* fusion, but also a secondary CTNNB1 p.S45V mutation, which was not identified in the original sample. Of note, this sample showed copy gain in the *RICTOR* gene, but at a level below the threshold for reporting as amplification. The patient was switched to alectinib 600 mg BID in July 2016 with a positive clinical response. However, due to myalgias and creatine kinase (CK) elevation, the dose was reduced to 450 mg BID. She had sustained clinical and radiologic response on alectinib until May 2017, when she showed evidence of worsening pleural and brain metastases. She showed increasing thoracocentesis requirement; therefore, right thoracoscopy with talc pleurodesis was performed in May 2017.

PD-L1 (pharmDx 22C3; Agilent; Santa Clara, CA, USA) immunohistochemical staining was performed on a pleural fluid cell block from May 2017, showing no PD-L1 expression (testing performed at PhenoPath; Seattle, Washington, USA). A third CGP profile was performed on a right parietal pleural excision from May 2017, again showing *EML4-ALK* fusion and the CTNNB1 p.S45V mutation. In this sample, *RICTOR* amplification was reported as a variant of unknown significance due to a non-focal pattern. In addition, tumor mutation burden (TMB) was reported as low at 4 mutations/Mb. (TMB information was not available on the two prior specimens.) [Figure 3](#F0003){ref-type="fig"} shows a comparison of the next generation sequencing data for the first three samples at *CTNNB1* codon 45.Figure 3Integrative Genomics Viewer screenshot demonstrating next generation sequencing data (FoundationOne) from three specimens (TRF123157, specimen from October 2015; TRF166853, from June 2016; TRF232300, from May 2017). The specimens from June 2016 and May 2017 both show a *CTNNB1* (NM_001904.4) c.133_134delTCinsGT, p.S45V dinucleotide substitution; however, this variant is not seen in the original specimen from October 2015.

In June 2017, the patient was switched to brigatinib 90 mg (this dosage was selected in order to limit CK elevation). However, she developed increasing disease, for which she received two cycles of carboplatin/pemetrexed. In March 2018, she was switched to lorlatinib (dose reduced to 75 mg).

The disease continued to progress, and a 4th CGP (FoundationOne CDx) was performed on a lung biopsy from December 2018, showing *EML4-ALK* fusion, CTNNB1 p.S45V, *RICTOR* amplification, and a new tertiary ALK p.I1171N mutation. TMB was again reported to be 4 mutations/Mb, and the tumor was reported to be microsatellite stable. PD-L1 showed high expression by immunohistochemistry (Ventana SP263; Roche Diagnostics; Tucson, AZ, USA). FISH for the *MET* gene was negative for high-level amplification (performed at Quest Diagnostics; Chantilly, VA, USA). Based on the *CTNNB1* mutation and *RICTOR* amplification in the patient's tumor, she was evaluated for clinical trials with therapeutic agents targeting GSK-3b or PI3K. However, in March 2019, the patient died due to complications of the disease. [Figure 4](#F0004){ref-type="fig"} summarizes the patient's clinical course, and [Table 1](#T0001){ref-type="table"} summarizes the duration and best response of each treatment.Table 1Duration and best response of each treatmentTreatmentDuration of treatment\
(months)Best response\
of treatmentCarboplatin, Paclitaxel, Bevacizumab2Partial responseCrizotinib (started without progression)5Partial responseAlectinib10.5Partial responseBrigatinib6Partial responseCarboplatin, Pemetrexed1.5Progressive diseaseLorlatinib9.5Partial response Figure 4Timeline of clinical course, including comprehensive genomic profiling results and therapy.

Discussion {#S0003}
==========

In 2011, the TKI crizotinib was approved by the US Food and Drug Administration for the treatment of *ALK*-rearranged NSCLC. Subsequently, multiple TKIs have been developed. However, several mechanisms of resistance to TKIs have also been identified. This includes secondary *ALK* mutations, downstream activation, and activation of alternative signaling pathways.[@CIT0002]--[@CIT0004] Acquired resistance usually develops over a period of several months, suggesting a clonal evolution process where resistant clones overgrow the sensitive ones. ALK p.I1171N, which was seen in our patient, is a well-described secondary resistance mutation that typically occurs after disease progression[@CIT0002] and is located in the tyrosine kinase domain. Our patient's tumor also showed *RICTOR* amplification upon initial CGP, and this alteration has been identified in up to 13% of all lung cancers.[@CIT0005] Activation of RICTOR-mTORC2 promotes cell proliferation and survival,[@CIT0005] and tumors showing *RICTOR* amplification have shown sensitivity to mTORC1/2 inhibitors.

However, the patient presented herein showed an initial clinical response to crizotinib. After the development of resistance, repeat tumor profiling showed a secondary CTNNB1 p.S45V variant. To our knowledge, concomitant *CTNNB1* mutations are extremely rare in *ALK*-rearranged NSCLC. In a study of Finnish NSCLC patients with *ALK* gene fusion and concomitant driver gene mutations, one patient was reported to have CTNNB1 p.S45P, as well as a mutation in *MET*; however, the clinical course and treatment information were not available.[@CIT0006]

*CTNNB1* mutations are seen in only 3--4% of NSCLC (cbioportal.org, accessed March 2019). *CTNNB1* encodes β-catenin, a critical effector of Wnt signaling and cellular adhesion.[@CIT0007] Exon 3 mutations, including the p.S45 mutational hotspot, are early events in the development of multiple cancers.[@CIT0007] Activating mutations result in altered cellular signaling, driving tumorigenesis. Furthermore, alterations in molecules involved in other signaling pathways, such as PI3K/AKT signaling, can modulate the Wnt pathway.[@CIT0007] In cell lines harboring *EML4-ALK*, the fusion has been shown to drive the phosphorylation of AKT and ERK, and this effect has been reduced through ALK inhibition.[@CIT0008] This suggests a possible mechanism for interaction with CTNNB1.[@CIT0009]--[@CIT0011] The CTNNB1 p.S45V mutation is exceedingly rare, but occurs at an important phosphorylation site for casein kinase-1 that is centrally involved in Wnt signaling.[@CIT0007]

For a variety of cancers, overexpression of immune checkpoint molecules in the tumor microenvironment has been shown to play a critical role in both antitumor immunity evasion and cancer progression.[@CIT0012] Our patient's tumor showed increased PD-L1 expression using the SP263 antibody. Although immune checkpoint inhibitors have been approved for use in a variety of tumors, some patients do not respond to these agents, and this de novo resistance may be related to immunosuppressive mechanisms within the tumor microenvironment.[@CIT0012] Wnt/β-catenin signaling has been associated with immune evasion[@CIT0012] and activating mutations in *CTNNB1* may result in modulation of the tumor microenvironment. Therefore, in addition to its potential impact on ALK inhibition, *CTNNB1* mutations have the potential to impact response to immunotherapy treatments. Due to the involvement of Wnt signaling in the pathogenesis of many tumors, a variety of therapeutic strategies are being developed to target this pathway.[@CIT0012] This includes inhibitors of Wnt signaling, antibodies against frizzled receptors and Dkk-1, and inhibitors of Wnt ligand secretion.[@CIT0012]

Recently, it was shown that constitutively activated ALK phosphorylates SMAD4, impairing SMAD4 DNA-binding and TGF-β tumor suppressor signaling.[@CIT0013] Furthermore, TKIs may have a role in reversing this effect.[@CIT0013] As previously discussed, β-catenin activation is associated with immunosuppression in the cancer microenvironment[@CIT0007] and resistance to immunotherapy. Therefore, immunomodulation by Wnt signaling may interfere with the effects of TKIs on TGF-β signaling, possibly leading to TKI-resistance.

Conclusion {#S0004}
==========

We present a patient with lung adenocarcinoma showing *ALK*-rearrangement with resistance to multiple TKIs. Serial CGP showed multiple genomic alterations developing over time through a process of clonal evolution. Although subsequent profiling showed a known resistance mutation in the *ALK* gene, the development of a possible activating mutation in the *CTNNB1* gene after initial clinical response suggests a possible biological mechanism for the patient's initial resistance. This case reflects the challenges of targeted therapeutics and highlights the importance of comprehensive genomic testing for utilizing targeted therapy in the context of clonal evolution. The *CTNNB1* mutation is particularly relevant to targeted therapy, given the role of β-catenin in the cancer microenvironment. However, further investigation, including functional analysis, is required to define the role of CTNNB1 p.S45V mutation in ALK-driven NSCLC and TKI-resistance. This may aid in the continuing development of therapeutic strategies for NSCLC.
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